

Canaan

Anil Singhal

Executive in Residence / West Coast
Since 2018

Anil is passionate about translating novel science into transformative medicines.

He currently serves as Chief Scientific Officer at OncoResponse, a company discovering cancer immunotherapies by interrogating the human immune system. He is also on the board of Surefire Medical.

Anil is the former Vice President of Early Oncology Development at AbbVie and Head of AbbVie's Redwood City site. During his tenure at AbbVie, he oversaw the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.

Anil has held senior roles in the US, Japanese and German biopharma / biotechnology industry for over 30 years leading to the approval of Prosorba in rheumatoid arthritis and talaporfin sodium in non-small cell lung cancer.

Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.

About Canaan

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With \$5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan's focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit canaan.com.